Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). It is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel. Pimecrolimus binds to the intracellular immunophilin FKBP12 and inhibits calcineurin phosphatase activity, reducing T cell activation and the release of proinflammatory cytokines such as interleukin 2 and interferon gamma. The active pharmaceutical ingredient is formulated as a 1% w/w cream for dermatological use with low systemic absorption after topical application; pharmacokinetic studies show minimal plasma exposure in most patients. The molecule is chemically stable under recommended storage conditions but is susceptible to hydrolytic and oxidative degradation under forced stress testing, which informs formulation choices and packaging. Analytical control is typically performed by reversed phase HPLC with UV detection for potency and related substance profiling and by LC-MS for structural identification of degradants.
Parent: Pimecrolimus / Ascomycin
Parent: Pimecrolimus
Impurity control for pimecrolimus concentrates on process related compounds and degradation products typically observed as demethylated, hydroxylated, epimeric and oxidation products. Typical analytical specifications set individual known related compounds at acceptance limits in the range of 0.2 to 0.5 percent of the active substance by area percent in HPLC, with an individual unspecified impurity reporting threshold around 0.1 to 0.2 percent and a total related substances limit commonly not to exceed 1.0 percent. Residual solvents and catalyst traces are controlled to ICH Q3C and Q3D limits with specific solvent limits reported in the regulatory dossier. Identification and quantification use forced degradation studies, reference impurity standards where available, orthogonal methods such as LC-MS and NMR, and validated stability indicating HPLC methods to ensure that impurities remain within established acceptance criteria throughout shelf life.
Pimecrolimus cream is used topically to treat mild to moderate atopic dermatitis in patients when topical corticosteroids are not suitable or when steroid sparing therapy is desired; it reduces inflammation and itching by inhibiting local T cell mediated immune responses.
No. Pimecrolimus 1% is not a corticosteroid. It is a calcineurin inhibitor with an immunomodulatory mechanism distinct from steroid action and is used as a steroid alternative for topical management of eczema.
No. Pimecrolimus is not the same as hydrocortisone. Hydrocortisone is a topical steroid that acts through glucocorticoid receptor mediated pathways, while pimecrolimus inhibits calcineurin via binding to FKBP12 and does not have steroid receptor activity.
Clinical response varies. Some patients report reduction in itching within days, while measurable improvement in inflammatory lesions is often seen over one to two weeks; maximum effect may require several weeks of consistent application depending on disease severity and treatment site.
